UPDATE : Wednesday, November 13, 2019
상단여백
HOME Policy
Korea ranks 6th in world in number of clinical trials
  • By Marian Chu
  • Published 2018.01.15 18:32
  • Updated 2018.01.15 18:32
  • comments 0

Korea ranked sixth in the world for the number of clinical trials conducted in the country, and Seoul topped the list with the most clinical trials per city last year, the Korea National Enterprise for Clinical Trials (KoNECT) said Monday.

Korea marked a historical first by accounting for 2.5 percent of all clinical trials registered with the U.S. National Institutes for Health’s ClinicalTrials.gov, making the country sixth regarding the number of global clinical tests, according to KoNECT data.

The U.S. had the most clinical trials in the world, taking up nearly 25 percent of the clinical trial protocol market share, according to KoNECT’s analysis of the clinical trials registered by pharmaceuticals last year.

After the U.S., Germany (5.3 percent) came in second place, followed by the U.K. (5 percent), Canada (3.9 percent) and China (3.7 percent).

Despite a 25 percent year-on-year decline of global clinical trials registered last year, Korea maintained the same number of clinical trials from 2016, the agency said. Domestically, KoNECT also approved 30 clinical trials in 2017, indicating a 4.8 percent increase from the previous year, it added.

Trials by multinational pharmaceuticals accounted for around 26 percent, while researcher-led studies accounted for 10 percent. The number of clinical trials registered by domestic pharmaceutical companies decreased 11 percent from 2016, KoNECT said.

The government has taken an active role in fostering the growth of Korean clinical trials for the past five years, with the aim of leading the global market.

“The propagation of clinical trials in Korea proves the superiority of executive capabilities and infrastructure of the country’s clinical trials and is the result of continuous government support,” KoNECT President Deborah Chee said.

It is necessary to improve the clinical development capacity of hospitals, academia, and institutes, to improve regulations continuously, and to introduce incentives for domestically developed new drugs to proceed to phase 3 studies, Chee added.

yjc@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Marian Chu
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top